New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›WisdomTree›WDNA

WDNA

WisdomTree BioRevolution UCITS ETF

Passive ETF Equity ESG Theme: BioTech & Genomics

The WDNA Exchange Traded Fund (ETF) is provided by WisdomTree. It is built to track an index: WisdomTree BioRevolution ESG Screened Index. The WDNA ETF provides physical exposure, so by buying it you actually own parts of all the 76 underlying holdings. The dividend policy is capitalization.

$27.15

-$0.75 (-2.70%) 2 days ago

8:00 AM 10/30/26 Closed

1D price range

$27.15$27.91

52W price range

$17.03$28.42

YTD Perf.

+46.27%

YTD Flows

Annualized volatility

Fund AuM

€39M

Share class AuM

€39M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

IE000O8KMPM1

TER

0.45%

Inception date

12/3/2021

Issuer

WisdomTree

Benchmark

WisdomTree BioRevolution ESG Screened Index

Replication method

Dividend policy

Capitalization

Compare similar ETFs

ETF Name	1w perf.
WDNA WisdomTree BioRevolution Fund	+4.62%
TMED T. Rowe Price Health Care ETF	+0.95%
IBBQ Invesco Nasdaq Biotechnology ETF	+4.67%
203780 Mirae Asset TIGER NASDAQ BIO ETF	+2.79%
BTEE iShares Nasdaq US Biotechnology UCITS ETF	+4.67%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	+2.63%
GNMX Corgi Genomics & Precision Medicine ETF	+4.10%
PBE Invesco Dynamic Biotechnology & Genome ETF	+3.93%
HTEC Robo Global Healthcare Technology and Innovation ETF	+2.32%
IBB iShares Biotechnology ETF	+4.75%
PINK Simplify Health Care ETF	+2.67%
CURE VanEck Genomics and Healthcare Innovators UCITS ETF	+2.59%
PJP Invesco Dynamic Pharmaceuticals ETF	+4.36%
FMED Fidelity Disruptive Medicine ETF	+2.78%
HELX Franklin Genomic Advancements ETF	+5.34%

API

PerformanceDec 31, 2025 - Oct 29, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

88.59%

Non-Energy Materials

5.21%

Consumer Non-Cyclicals

3.50%

Unavailable

2.70%

Latest WDNA news

No content available for this fund

FAQ about WDNA

WDNA is a passively managed ETF that invests in the Developed Market Blended Cap segment.

WDNA tracks the WisdomTree BioRevolution ESG Screened Net Return Index - USD, through a full replication replication method.

WDNA carries a total expense ratio (TER) of 0.45%.

WDNA was introduced to the market on December 3, 2021.

WisdomTree BioRevolution UCITS ETF, WDNA, is provided by WisdomTree. Learn more about WisdomTree here.

WDNA oversees €39M in assets as of October 29, 2026.

WDNA follows a capitalizing, meaning it reinvests income within the fund.

As of September 30, 2026, WDNA has significant geographic allocations in USA, Germany and Switzerland.

As of September 30, 2026, WDNA focuses largely on Healthcare, Non-Energy Materials and Consumer Non-Cyclicals.

As of September 30, 2026, WDNA holds 76 positions in its portfolio, with 49.15% of assets concentrated in its top 15 holdings.

As of September 30, 2026, WDNA top three holdings include Moderna, Inc., Twist Bioscience Corp. and Eli Lilly & Co..

The base currency of WDNA is USD.

Top 10 holdings

Data as of 09/30/26

Moderna, Inc.

10.08%

Twist Bioscience Corp.

9.27%

Eli Lilly & Co.

3.52%

10X Genomics, Inc.

3.46%

Natera, Inc.

3.05%

Tempus AI, Inc.

2.82%

Johnson & Johnson

2.74%

Immunome, Inc.

2.07%

Darling Ingredients, Inc.

1.90%

United Therapeutics Corp.

1.89%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

WisdomTree BioRevolution UCITS ETF

FAQ about WDNA

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US